A carregar...
Cost burden of diffuse large B-cell lymphoma
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogenous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. AREAS COVERED: We review the cost burden of DLBCL and cost-effectiveness of DL...
Na minha lista:
| Publicado no: | Expert Rev Pharmacoecon Outcomes Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6930962/ https://ncbi.nlm.nih.gov/pubmed/31623476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737167.2019.1680288 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|